1-(4-(3-amino-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperazin-1-yl)-2-(3,4-dichlorophenyl)ethanone

ID: ALA5286179

Max Phase: Preclinical

Molecular Formula: C17H17Cl2N7O

Molecular Weight: 406.28

Names and Identifiers

Canonical SMILES:  Nc1nnc2ccc(N3CCN(C(=O)Cc4ccc(Cl)c(Cl)c4)CC3)nn12

Standard InChI:  InChI=1S/C17H17Cl2N7O/c18-12-2-1-11(9-13(12)19)10-16(27)25-7-5-24(6-8-25)15-4-3-14-21-22-17(20)26(14)23-15/h1-4,9H,5-8,10H2,(H2,20,22)

Standard InChI Key:  SGEAOXVFFKNMRI-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
   -0.9894   -0.8245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7040   -0.4122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4185   -0.8245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1331   -0.4122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8477   -0.8245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8477   -1.6490    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1331   -2.0613    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4185   -1.6490    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5622   -2.0613    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -4.5622   -0.4122    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -0.2748   -0.4122    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2748    0.4122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4397    0.8245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1543    0.4122    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1543   -0.4122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4397   -0.8245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8689    0.8245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8689    1.6490    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5835    2.0613    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2980    1.6490    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2980    0.8245    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5835    0.4122    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.0951    0.5770    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5622    1.2367    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.0951    1.8964    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3425   -0.2198    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9894   -1.6490    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  3  8  2  0
  7  8  1  0
  6  9  1  0
  5 10  1  0
  1 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 11 16  1  0
 15 16  1  0
 14 17  1  0
 18 17  1  0
 19 18  2  0
 20 19  1  0
 20 21  1  0
 22 21  1  0
 17 22  2  0
 23 21  1  0
 24 23  2  0
 25 20  2  0
 24 25  1  0
 23 26  1  0
  1 27  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA5286179

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 406.28

Molecular Weight (Monoisotopic): 405.0872

AlogP: 1.90

#Rotatable Bonds: 3

Polar Surface Area: 92.65

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 2.49

CX LogP: 2.37

CX LogD: 2.37

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.71

Np Likeness Score: -2.21

References

1. Oboh E, Teixeira JE, Schubert TJ, Maribona AS, Denman BN, Patel R, Huston CD, Meyers MJ..  (2023)  Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633.,  86  [PMID:37148788] [10.1016/j.bmc.2023.117295]

Source

Source(1):

• Scientific Literature